The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy

BMC Cancer

Table 4 Multiple hypothesis testing of factors associated with survival

Breast cancer subtypes	RFS			OS			DMFS
Breast cancer subtypes	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
ER status
ER+	1.85	1.57–2.18	< 0.001	2.61	1.86–3.68	< 0.001	2.92	2.09–4.07	< 0.001
ER-	1.18	0.9–1.18	0.23	1.24	0.8–1.92	0.34	1.4	0.9–2.17	0.13
PR status
PR+	3.4	2.09–5.55	< 0.001	6.34	1.26–31.88	ns, 0.011	3.92	1.15–13.32	ns, 0.018
PR-	1.51	1.11–2.05	ns, 0.0081	2.79	0.99–7.82	ns, 0.042	3.39	1.88–6.11	< 0.001
HER2 status
HER2+	1.73	1.17–2.56	ns, 0.0053	3.42	1.52–7.72	0.0017	1.78	0.94–3.39	ns, 0.073
HER2-	2.12	1.79–2.51	< 0.001	1.7	1.37–2.12	< 0.001	1.93	1.58–2.36	< 0.001
Lymph node status
Lymph node+	2.19	1.67–2.88	< 0.001	1.72	1.18–2.5	ns, 0.0044	2.03	1.4–2.94	< 0.001
Lymph node-	1.82	1.52–2.17	< 0.001	3	1.88–4.78	< 0.001	2.39	1.8–3.19	< 0.001
Grade
1	3.12	1.8–5.42	< 0.001	3.19	1.28–7.96	ns, 0.0087	2.79	1.23–6.33	ns, 0.011
2	1.99	1.56–2.55	< 0.001	2.55	1.67–3.89	< 0.001	2.61	1.85–3.68	< 0.001
3	1.35	1.07–1.7	ns, 0.011	1.25	0.89–1.77	0.19	1.75	1.13–2.73	ns, 0.012
TP53 status
Mutated	0.77	0.48–1.26	0.3	0.69	0.34–1.42	0.32	0.56	0.26–1.22	0.14
Wild type	1.82	1.16–2.85	ns, 0.0077	2.56	1.38–4.76	0.0021	3.67	1.76–7.63	< 0.001

ns Not significant after correction for multiple hypothesis testing; bold faced: remained significant

ISSN: 1471-2407